Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Mergenthaler

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Frontiers in Neurology|March 12, 2024
Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters - a pilot studyAnne Mehnert, Sivan Bershan, Jil Kollmus-Heege, et al.
Annals of Clinical and Translational Neurology|November 20, 2025
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and EculizumabLea Gerischer, Frauke Stascheit, Maximilian Mönch, et al.
Thyroid : Official Journal of the American Thyroid Association|March 8, 2020
Spatiotemporal Changes of Cerebral Monocarboxylate Transporter 8 ExpressionNina-Maria Wilpert, Martin Krueger, Robert Opitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2012
Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic statePhilipp Mergenthaler, Anja Kahl, Anne Kamitz, et al.
Neurology|July 6, 2026
Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis RegistryHannah Preßler, Frauke Stascheit, Annette Aigner, et al.
Journal of Neuroinflammation|April 13, 2022
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patientsChristopher Nelke, Frauke Stascheit, Carmen Eckert, et al.
Cell Chemical Biology|April 11, 2017
A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes NeuroprotectionXin Niu, Hetal Brahmbhatt, Philipp Mergenthaler, et al.
Neurology|December 6, 2019
Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 casesBernhard Neumann, Klemens Angstwurm, Philipp Mergenthaler, et al.
Journal of Neurology|September 27, 2022
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravisFrauke Stascheit, Ulrike Grittner, Sarah Hoffmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2022
Eculizumab versus rituximab in generalised myasthenia gravisChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Frontiers in Neurology|March 12, 2024
Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters - a pilot studyAnne Mehnert, Sivan Bershan, Jil Kollmus-Heege, et al.
Annals of Clinical and Translational Neurology|November 20, 2025
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and EculizumabLea Gerischer, Frauke Stascheit, Maximilian Mönch, et al.
Thyroid : Official Journal of the American Thyroid Association|March 8, 2020
Spatiotemporal Changes of Cerebral Monocarboxylate Transporter 8 ExpressionNina-Maria Wilpert, Martin Krueger, Robert Opitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2012
Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic statePhilipp Mergenthaler, Anja Kahl, Anne Kamitz, et al.
Neurology|July 6, 2026
Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis RegistryHannah Preßler, Frauke Stascheit, Annette Aigner, et al.
Journal of Neuroinflammation|April 13, 2022
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patientsChristopher Nelke, Frauke Stascheit, Carmen Eckert, et al.
Cell Chemical Biology|April 11, 2017
A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes NeuroprotectionXin Niu, Hetal Brahmbhatt, Philipp Mergenthaler, et al.
Neurology|December 6, 2019
Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 casesBernhard Neumann, Klemens Angstwurm, Philipp Mergenthaler, et al.
Journal of Neurology|September 27, 2022
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravisFrauke Stascheit, Ulrike Grittner, Sarah Hoffmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2022
Eculizumab versus rituximab in generalised myasthenia gravisChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
Pageof 5